ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan Springfield, MA — October 24, 2018 — The ERAS Cardiac Surgery Society presented its recent consensus statement at the 32nd European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Milan, Italy, last week as part of an educational session. This dedicated ERAS Cardiac Surgery session was held during EACTS, the world’s largest cardiothoracic surgery focused professional conference with international speakers across all subspecialties. ERAS Cardiac Surgery is a patient safety organization with the mission to facilitate optimization of perioperative care of cardiac surgical patients through collaborative discovery, analysis, expert consensus, and dissemination of best
Anaheim, CA – August 21, 2018— ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that it has been awarded a group purchasing agreement for the Chest Drainage Products category with Premier. Effective July 15th 2018, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for: PleuraFlow Active Clearance Technology (ACT) System; PleuraFlow Active Clearance Technology (ACT) System with FlowGlide; and PleuraFlow POD – High Capacity Dry Thoracic Drainage Canister. “ClearFlow is proud to now be able to bring its Active Clearance Technology devices to Premier members under these new arrangements with one of
Boston, MA – May 29th, 2018 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) & Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural Effusions and ICU Resources in patients undergoing Cardiac Surgery.” This data stems from a trial evaluating the use of the PleuraFlow® Active Clearance Technology® (ACT®) System to prevent retained blood complications in heart
San Diego, California – May 2, 2018 – ClearFlow Inc. has announced that an international society of leading heart surgeons known as ERAS® Cardiac Surgery presented evidenced-based expert consensus statements at the 98th annual meeting of the American Association for Thoracic Surgeons on April 28, 2018. Amongst key recommendations to promote enhanced patient outcomes after cardiac surgery is the use of Active Clearance techniques to maintain chest tube patency. The PleuraFlow® ACT® System is the only FDA cleared device with the indication to prevent or minimize retained blood in patients recovering from heart surgery. The PleuraFlow ACT System is indicated for use during cardiothoracic surgical procedures and chest trauma.
–ClearFlow spokespeople cite review article as latest piece of mounting evidence pertaining to urgent need for managing retained blood after surgery– Anaheim, CA – February 1, 2018—ClearFlow Inc., a medical device company based in Anaheim, California, has announced that the cover of the January, 2018 issue of The Annals of Thoracic Surgery features a review article that elucidates the biological mechanisms by which retained shed mediastinal blood can trigger postoperative atrial fibrillation (POAF) in susceptible individuals as well as how this could represent a new target for prevention of POAF. The article can be viewed online here: http://www.annalsthoracicsurgery.org/article/S0003-4975(17)31095-0/fulltext The article’s author group is comprised of key opinion leaders on the